ROSY-F: Roll-Over Study for Participants Who Have Completed a Previous Study with Benralizumab (Fasenra) and Are Judged by the Investigator to Clinically Benefit from Continued Treatment

Status

Not yet recruiting

Phases

Phase 3

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2025-523307-29-00

Enrollment

Registered

2026-08-04

Start date

Unknown

Completion date

Unknown

Last updated

2026-08-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hypereosinophilic Syndrome (HES), Eosinophilic Granulomatosis with Polyangiitis (EGPA), Asthma

Brief summary

Safety will be evaluated by monitoring and assessing SAEs and non-serious AEs reported throughout the study and until 8 weeks after the last dose of benralizumab.

Interventions

DRUGFasenra 30 mg solution for injection in pre-filled syringe

DRUGBenralizumab

Eligibility

Sex/Gender

All

Age

0 Years to No maximum

Design outcomes

Primary

Measure	Time frame
Safety will be evaluated by monitoring and assessing SAEs and non-serious AEs reported throughout the study and until 8 weeks after the last dose of benralizumab.	—

Outcome results

None listed

Source: EU CTIS · Data processed: Aug 7, 2026